Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | UBE2I | P63279 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556123 | 0.86 | MTNR1A (0.44) | TAAR1CASP6SMN1; SMN2HPGDMTNR1A | |
| SCHEMBL534744 | 0.83 | MTNR1A (0.51) | MTNR1AMTNR1B | |
| SCHEMBL17729329 | 0.78 | ALDH1A1 (0.45) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL555531 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPT | |
| SCHEMBL555438 | 0.76 | ALDH1A1 (0.49) | TAAR1SMN1; SMN2HPGDMTNR1AMTNR1B | |
| SCHEMBL31064494 | 0.71 | FFAR1 (0.52) | — | |
| SCHEMBL3623135 | 0.70 | KDM4E (0.43) | SMN1; SMN2HPGDGAAMAPT | |
| SCHEMBL20945353 | 0.69 | ALDH1A1 (0.44) | SMN1; SMN2HPGDGAAMAPT | |
| SCHEMBL533834 | 0.68 | MTNR1A (0.59) | MTNR1AMTNR1B | |
| SCHEMBL22526773 | 0.68 | UCHL1 (0.37) | HPGDMTNR1AMTNR1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | TAAR1 1781/4885CASP6 1940/4885SMN1; SMN2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.